Answer
Maribavir is expected to increase rosuvastatin exposure and lead to undesirable effects because it inhibits the BCRP transporter in vitro at clinically relevant concentrations.
Sources for this answer
- LIVTENCITY 200 mg film coated tabletsTakeda UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 5Document updated
Sources checked